
Vaccine Adjuvants Market By Product Type (Pathogen, Adjuvant Emulsion, And Others), By Route Of Administration (Oral, Intradermal, Subcutaneous), By Disease Type, By Application (Research And Commercial), and Region - Global Forecast to 2023
-
3318
-
Aug 2018
-
169
-
PDF
-
-
Request Covid 19 Impact
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
-
Global Vaccine Adjuvants Market: Introduction
The global vaccine adjuvants market is expected to value at approximately US$ 0.5 Bn in 2019 and is expected to register a CAGR of 10.4%.
Vaccine adjuvants help the body to build a strong immune response to protect the person from the disease. Adjuvants are added to vaccines to work better by improving the response of the body to vaccination and reducing the number of vaccine doses given to patients.
Major factors driving the growth of the global vaccine adjuvants market are increasing technological advancements focusing on improved and long-lasting vaccines for existing and emerging chronic diseases and growing government expenditure on research and development of adjuvant vaccines. Additionally, R&D enables evaluating adjuvant safety and efficacy for improving and standardizing animal models and correlating different immune responses with individual characteristics such as age, gender, ethnicity, genetics, underlying chronic illness, etc.
Increasing demand for vaccine adjuvants for preventing various high predominant chronic diseases such as arthritis, cancer, diabetes, epilepsy, obesity, allergy, etc. is projected to drive the growth of the target market. Vaccines are among some of the most effective medical inventions against various infectious diseases, and sometimes require a molecule in conjugation that enhances its immune response.
However, less safety pertaining to vaccine adjuvants is expected to hamper the growth of the global target market to a certain extent. Adjuvants act as immune-stimulants and may induce unwanted immune processes that could trigger the arrival of the immune-mediated disease in vulnerable individuals.
The development of new vaccine adjuvants required for pandemic diseases like influenza is a factor expected to create a lucrative opportunity for driving the growth of the target market in the next coming years.
Global Vaccine Adjuvants Market Analysis, by Product Type
On the basis of product type segmentation, the particulate segment is expected to contribute a major revenue share and is projected to maintain its dominance over the forecast period. This dominance is attributed to the increasing adoption of pathogen adjuvants for the treatment of various diseases such as hepatitis B, and human papillomavirus coupled with the increasing prevalence of these diseases across the globe.
Global Vaccine Adjuvants Market Analysis, by Route of Administration
On the basis of route of administration segmentation, the intramuscular segment is expected to contribute a major revenue share of the market and is expected to maintain its dominance over the forecast period. The intramuscular segment is projected to register a significant CAGR of over 10.2%, over the forecast period, owing to increasing demand for intramuscular vaccine adjuvants to treat various diseases such as influenza, human papillomavirus (HPV), coupled with the increasing prevalence of these diseases.
Global Vaccine Adjuvants Market Analysis, by Disease Type
On the basis of disease type segmentation, the infectious disease segment is expected to contribute a major revenue share of the market and is expected to maintain its dominance over the forecast period. The infectious disease segment is projected to register a significant CAGR of over 10.1%, over the forecast period. The growing prevalence of infectious diseases such as malaria, influenza, hepatitis A, B, & C, and others in developed and developing countries is expected to support the revenue growth of the segment.
Global Vaccine Adjuvants Market Analysis, by Application
On the basis of application segmentation, the research segment is expected to contribute a major revenue share of the market and is expected to maintain its dominance over the forecast period. The research segment is projected to register a significant CAGR of over 10%, over the forecast period, owing to various research institutes and government organizations for R&D of adjuvants and vaccines.
Global Vaccine Adjuvants Market Analysis, by Region:
The market in North America accounted for a major revenue share in the global vaccine adjuvants market in 2018 and is projected to maintain its dominance over the forecast period. The North American vaccine adjuvants market is expected to register a significant CAGR during the forecast period. Demand for vaccine adjuvants has been increasing significantly due to the presence of advanced medical facilities and developed healthcare infrastructure, coupled with the high adoption of technologically advanced healthcare products and devices in countries in the region. In addition, increasing government initiatives for spreading awareness about various infectious diseases and cancers, coupled with favorable reimbursement policies, is another factor expected to drive revenue growth of the market in the region.
The Asia Pacific market is projected to register the highest CAGR of over 10.6% in the global vaccine adjuvants market during the forecast period. This can be attributed to the increasing incidence of various infectious diseases, the presence of a large patient pool, and increasing government initiatives for spreading awareness about the treatment of various diseases, especially in emerging economies such as China and India. Furthermore, the increasing geriatric population and increasing incidence of obesity and diabetes, which could lead to severe health problems including cancer, are among other factors expected to propel the need for developed and well-equipped medical care facilities, which in turn is projected to fuel the growth of the Asia Pacific vaccine adjuvants market over the forecast period
The market in Middle East & Africa accounted for considerable revenue share in the global vaccine adjuvants market and is projected to register a CAGR of over 9% over the forecast period.
Global Vaccine Adjuvants Market segmentation:
Segmentation on The Basis of Product Type:
- Pathogen
- Adjuvant Emulsion
- Particulate
- Combination
- Others
Segmentation on The Basis of Route of Administration:
- Oral
- Intradermal
- Intranasal
- Intramuscular
- Subcutaneous
Segmentation on The Basis of Disease Type:
- Infectious Disease
- Cancer
Segmentation on The Basis of Application:
- Research
- Commercial
Segmentation on the Basis of Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
-
- Brenntag Biosector A/S
- CSL Limited
- Air Liquide S.A.
- Agenus Inc.
- Novavax, Inc.
- Associated British Foods plc (SPI Pharma, Inc.)
- InvivoGen Inc.
- Avanti Polar Lipids, Inc.
- MVP Laboratories Inc.
- OZ Biosciences
-
- 1 Chapter 1
- 1.1 Preface
- 1.2 Assumptions
- 1.3 Abbreviations
- 2 Chapter 2
- 2.1 Report Description
- 2.1.1 Market Definition and Scope
- 2.2 Executive Summary
- 2.2.1 Market Snapshot, By Product Type
- 2.2.2 Market Snapshot, By Route of Administration
- 2.2.3 Market Snapshot, By Disease Type
- 2.2.4 Market Snapshot, By Application
- 2.2.5 Market Snapshot, By Region
- 2.2.6 Prudour Opportunity Map Analysis
- 2.1 Report Description
- 3 Chapter 3
- 3.0.1 Global Vaccine Adjuvants Market Dynamics
- 3.0.2 Drivers (D)
- 3.0.3 Restraints (R)
- 3.0.4 Opportunities
- 3.0.5 Trends
- 3.0.6 DR Impact Analysis
- 3.0.7 PEST Analysis
- 3.0.8 PORTER’S Five Forces Analysis
- 3.0.9 Value Chain Analysis
- 3.0.10 Regulatory Scenario
- 3.0.11 Pipeline Assessment
- 3.0.12 Epidemiology
- 3.0.13 Reimbursement Scenario
- 3.0.14 Pricing Analysis
- 4 Chapter 4
- 4.0.1 Global Vaccine Adjuvants Market Analysis, by Product Type
- 4.0.2 Overview
- 4.0.3 Segment Trends
- 4.0.4 Market Value (US$ Mn) and Forecast, 2017-2027
- 4.1 Pathogen
- 4.1.1 Overview
- 4.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 4.2 Adjuvant Emulsion
- 4.2.1 Overview
- 4.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 4.3 Particulate
- 4.3.1 Overview
- 4.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 4.4 Combination
- 4.4.1 Overview
- 4.4.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 4.5 Others
- 4.5.1 Overview
- 4.5.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 5 Chapter 5
- 5.0.1 Global Vaccine Adjuvants Market Analysis, by Route of Administration
- 5.0.2 Overview
- 5.0.3 Segment Trends
- 5.0.4 Market Value (US$ Mn) and Forecast, 2017-2027
- 5.1 Oral
- 5.1.1 Overview
- 5.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 5.2 Intradermal
- 5.2.1 Overview
- 5.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 5.3 Intranasal
- 5.3.1 Overview
- 5.3.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 5.4 Intramuscular
- 5.4.1 Overview
- 5.4.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 5.5 Subcutaneous
- 5.5.1 Overview
- 5.5.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 6 Chapter 6
- 6.0.1 Global Vaccine Adjuvants Market Analysis, by Disease Type
- 6.0.2 Overview
- 6.0.3 Segment Trends
- 6.0.4 Market Value (US$ Mn) and Forecast, 2017-2027
- 6.1 Infectious Disease
- 6.1.1 Overview
- 6.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 6.2 Cancer
- 6.2.1 Overview
- 6.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 7 Chapter 7
- 7.0.1 Global Vaccine Adjuvants Market Analysis, by Application
- 7.0.2 Overview
- 7.0.3 Segment Trends
- 7.0.4 Market Value (US$ Mn) and Forecast, 2017-2027
- 7.1 Research
- 7.1.1 Overview
- 7.1.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 7.2 Commercial
- 7.2.1 Overview
- 7.2.2 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 8 Chapter 8
- 8.0.1 Global Vaccine Adjuvants Market Analysis, by Region
- 8.0.2 Overview
- 8.0.3 Regional Trends
- 8.0.4 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.0.5 Market Attractiveness Index
- 8.1 Global Vaccine Adjuvants Market Analysis, by North America
- 8.1.1 Overview
- 8.1.2 Country Trends
- 8.1.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 8.1.4 US
- 8.1.4.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.1.5 Canada
- 8.1.5.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.2 Global Vaccine Adjuvants Market Analysis, by Europe
- 8.2.1 Overview
- 8.2.2 Country Trends
- 8.2.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 8.2.4 Germany
- 8.2.4.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.2.5 UK
- 8.2.5.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.2.6 France
- 8.2.6.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.2.7 Russia
- 8.2.7.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.2.8 Italy
- 8.2.8.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.2.9 Rest of Europe
- 8.2.9.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.3 Global Vaccine Adjuvants Market Analysis, by Asia Pacific
- 8.3.1 Overview
- 8.3.2 Country Trends
- 8.3.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 8.3.4 China
- 8.3.4.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.3.5 India
- 8.3.5.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.3.6 Japan
- 8.3.6.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.3.7 Australia
- 8.3.7.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.3.8 Rest of Asia Pacific
- 8.3.8.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.4 Global Vaccine Adjuvants Market Analysis, by Latin America
- 8.4.1 Overview
- 8.4.2 Country Trends
- 8.4.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 8.4.4 Brazil
- 8.4.4.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.4.5 Mexico
- 8.4.5.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.4.6 Rest of Latin America
- 8.4.6.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.5 Global Vaccine Adjuvants Market Analysis, by Middle East & Africa
- 8.5.1 Overview
- 8.5.2 Country Trends
- 8.5.3 Market Value (US$ Mn) and Forecast, and Y-o-Y Growth, 2017-2027
- 8.5.4 GCC
- 8.5.4.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.5.5 Israel
- 8.5.5.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.5.6 South Africa
- 8.5.6.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 8.5.7 Rest of Middle East & Africa
- 8.5.7.1 Market Value (US$ Mn) and Forecast, 2017-2027
- 9 Chapter 9
- 9.0.1 Company Share Analysis
- 9.0.2 Company Profiles
- 9.1 Brenntag Biosector A/S
- 9.1.1 Company Overview
- 9.1.2 Product Portfolio
- 9.1.3 Contact Information
- 9.2 CSL Limited
- 9.2.1 Company Overview
- 9.2.2 Product Portfolio
- 9.2.3 Financial Overview
- 9.2.4 Recent Developments
- 9.2.5 SWOT Analysis
- 9.2.6 Contact Information
- 9.3 Air Liquide S.A.
- 9.3.1 Company Overview
- 9.3.2 Product Portfolio
- 9.3.3 Financial Overview
- 9.3.4 Recent Developments
- 9.3.5 SWOT Analysis
- 9.3.6 Contact Information
- 9.4 Agenus, Inc.
- 9.4.1 Company Overview
- 9.4.2 Product Portfolio
- 9.4.3 Recent Developments
- 9.4.4 Contact Information
- 9.5 Novavax, Inc.
- 9.5.1 Company Overview
- 9.5.2 Product Portfolio
- 9.5.3 Financial Overview
- 9.5.4 Recent Developments
- 9.5.5 SWOT Analysis
- 9.5.6 Contact Information
- 9.6 Associated British Foods plc (SPI Pharma, Inc.)
- 9.6.1 Company Overview
- 9.6.2 Product Portfolio
- 9.6.3 Financial Overview
- 9.6.4 SWOT Analysis
- 9.6.5 Contact Information
- 9.7 InvivoGen Inc.
- 9.7.1 Company Overview
- 9.7.2 Product Portfolio
- 9.7.3 Contact Information
- 9.8 Avanti Polar Lipids, Inc.
- 9.8.1 Company Overview
- 9.8.2 Product Portfolio
- 9.8.3 Contact Information
- 9.9 MVP Laboratories, Inc.
- 9.9.1 Company Overview
- 9.9.2 Product Portfolio
- 9.9.3 Contact Information
- 9.10 OZ Biosciences
- 9.10.1 Company Overview
- 9.10.2 Product Portfolio
- 9.10.3 SWOT Analysis
- 9.10.4 Contact Information
- 10 Chapter 10
- 10.0.1 Research Methodology
- 10.0.2 About Us
- 1 Chapter 1
OUR CLIENTS
Don't just take our word. We are trusted by these great companies!